[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356730-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356730-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","neutrophil-to-lymphocyte-ratio-as-a-prognostic-factor-of-survival-outcomes-in-head-and-neck-squamous-cell-carcinoma-receiving-neoadjuvant-immunotherapy","Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy","","The neutrophil-to-lymphocyte ratio (NLR) functions as a prognostic marker in cancers treated with immune checkpoint inhibitors by linking systemic inflammation to antitumor immune activity. A retrospective cohort study evaluates NLR’s predictive value in head and neck squamous cell carcinoma patients receiving neoadjuvant ICI therapy. Using pre-treatment NLR thresholds derived from ROC analysis, overall survival and disease-free survival are analyzed with Kaplan–Meier and multivariable Cox models. Low NLR shows independent improvement in OS and DFS.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/neutrophil-to-lymphocyte-ratio-as-a-prognostic-factor-of-survival-outcomes-in-head-and-neck-squamous-cell-carcinoma-receiving-neoadjuvant-immunotherapy/356730/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/neutrophil-to-lymphocyte-ratio-as-a-prognostic-factor-of-survival-outcomes-in-head-and-neck-squamous-cell-carcinoma-receiving-neoadjuvant-immunotherapy/356730.png","ImageObject",300,407,{"name":42,"@type":43},"วิน","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was the NLR calculated in this study?","Question",{"text":63,"@type":64},"Pre-treatment NLR was computed from absolute neutrophil counts and absolute lymphocyte counts measured before starting neoadjuvant ICI therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which cutoff for NLR was associated with better outcomes?",{"text":68,"@type":64},"NLR \u003C 4.14 was associated with improved overall survival and disease-free survival compared with NLR ≥ 4.14.",{"name":70,"@type":61,"acceptedAnswer":71},"What statistical methods were used to evaluate survival outcomes?",{"text":72,"@type":64},"Overall survival and disease-free survival were assessed with Kaplan–Meier curves and multivariable Cox proportional hazards regression models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356730,1790245173,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nNeutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy  \nPablo Llerena1 | Praneet C. Kaki1  | Kathryn Nunes1 | Eric Mastrolonardo1 | Kelly Bridgham1 | Annie E. Moroco1 | Hani Samarah1  | Mouadh Barbirou2,3 | David Baek4  | Chun Wang2 | Voichita Bar Ad5 | David M. Cognetti1 | Joseph M. Curry1,3 | Jennifer M. Johnson1,2,3 | Hushan Yang2,3 | Larry A. Harshyne3,6 | Adam J. Luginbuhl1,3  \n1Department of Otolaryngology—Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA | 2Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA | 3Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA | 4Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA | 5Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA | 6Department of Microbiology & Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA  \nCorrespondence: Adam J. Luginbuhl ([adam.luginbuhl@jefferson.edu](adam.luginbuhl@jefferson.edu))  \nReceived: 16 October 2024 | Revised: 30 January 2026 | Accepted: 19 February 2026  \nKeywords: disease-free survival | HNSCC | immune checkpoint inhibition | overall survival | serological markers  \nABSTRACT  \nPurpose: The neutrophil-to-lymphocyte ratio (NLR) is a prognostic marker in cancers treated with immune checkpoint inhibitors (ICI), reflecting the link between inflammation and cancer immune response. This study examines NLR's prognostic value in head and neck squamous cell carcinoma (HNSCC) patients receiving neoadjuvant ICI therapy, focusing on its potential as an independent predictor of overall survival (OS) and disease-free survival (DFS) .  \nMethods: We conducted a retrospective cohort study including three neoadjuvant trials: durvalumab ± metformin, nivolumab ± tadalafil, or nivolumab ± BMS-986205 from 2017 to 2022. Pre-treatment NLR was calculated using absolute neutrophil and absolute lymphocyte counts obtained before neoadjuvant ICI initiation. The optimal pre-treatment NLR cut-off was identified using receiver operating characteristic (ROC) curve analysis. OS and DFS were assessed using Kaplan–Meier and multivariable Cox proportional hazards regression models.  \nResults: A total of 97 patients met inclusion criteria. NLR \u003C 4.14 was associated with improved overall survival (HR 0.07, 95% CI 0.01–0.30, p \u003C 0.001) and DFS (HR 0.21, 95% CI 0.08–0.54, p = 0.001) compared to NLR ≥4.14. NLR \u003C 4.14 remained independently associated with improved OS (HR 0.14, 95% CI 0.02–0.78, p = 0.025) and DFS (HR 0.25, 95% CI 0.07–0.87, p = 0.030) on multivariable Cox regression. The survival benefit of NLR \u003C 4.14 persisted after sub-stratification for p16 status, ICI pathologic response status, and ICI trial.  \nConclusion: Low NLR was independently associated with improved OS and DFS among patients with HNSCC who received neoadjuvant ICI. These findings suggest the potential utility of the NLR in improving patient selection.  \n1 | Introduction  \nManagement of locoregionally advanced head and neck squamous cell carcinoma (HNSCC) remains challenging with high  \nrates of treatment failure and disease recurrence [1] . Recently, immune checkpoint inhibitors (ICIs) have been incorporated into the standard-of-care management of recurrent or metastatic (R/M) HNSCC. Pembrolizumab and nivolumab  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71693 1 of 9  \n[https://doi.org/10.1002/cam4.71693](https://doi.org/10.1002/cam4.71693)  \n(anti-progr","cbCaieoWnSCIlPlK","https://ap.wps.com/l/cbCaieoWnSCIlPlK","pdf",1368562,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Methods\n## Study Population and Design","[{\"question\":\"How was the NLR calculated in this study?\",\"answer\":\"Pre-treatment NLR was computed from absolute neutrophil counts and absolute lymphocyte counts measured before starting neoadjuvant ICI therapy.\"},{\"question\":\"Which cutoff for NLR was associated with better outcomes?\",\"answer\":\"NLR \\u003c 4.14 was associated with improved overall survival and disease-free survival compared with NLR ≥ 4.14.\"},{\"question\":\"What statistical methods were used to evaluate survival outcomes?\",\"answer\":\"Overall survival and disease-free survival were assessed with Kaplan–Meier curves and multivariable Cox proportional hazards regression models.\"}]","Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy | PDF",1790126984,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9468bb48c4b03cb504e5c245b654b66d.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/759c46a2a4e29d65bc062c4ea16b36ca.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18986281afbe12b4084685a2b554098e.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d055d17171d7ccf39faaaf5e661d8e5.webp",980,1287]